Skip to main content
. Author manuscript; available in PMC: 2012 Oct 3.
Published in final edited form as: Cancer Res. 2010 Aug 31;70(19):7442–7454. doi: 10.1158/0008-5472.CAN-10-0247

Figure 2. TLR2 engagement on pmel CD8 T-cells enhances cytolytic function against a weakly immunogenic melanoma tumor.

Figure 2

(A and B) Purified pmel CD8 T-cells were activated with mgp100-pulsed MyD88−/− splenocytes with or without TLR2 agonist and five days later, cytolytic activity against B16 melanoma cells was determined at different effectors to target ratios (B) or against EL4 cells pulsed with varying concentrations of mgp100 peptide at a 3:1 E:T ratio. (C) In vivo cytotoxicity assays were conducted as described in the Materials and Methods section. Briefly, resting pmel, TLR2−/−pmel, or MyD88−/−pmel T-cells were were injected (i.v.) into MyD88−/− mice. One day later mice received CFSEhigh mgp100-peptide–pulsed MyD88−/− target cells and CFSElow cells pulsed with an irrelevant H-2Db–restricted peptide with or without the TLR1/2 agonist. D) The percentage of targets recovered from spleens 24 hours after adoptive transfer was evaluated by FACS analysis. Data are representative of 2 experiments (5 mice per group). *P ≤0.02; ANOVA; n.s. not significant.